. "Pokroky ve studiu n\u00E1dorov\u00E9 transformace v\u00FDrazn\u011B usnad\u0148uj\u00ED n\u00E1vrhy modern\u00EDch a specifick\u00FDch terapeutick\u00FDch metod. Proteinkinasy pat\u0159\u00ED ke kli\u010Dov\u00FDm slo\u017Ek\u00E1m bun\u011B\u010Dn\u00FDch sign\u00E1ln\u00EDch soustav a d\u00EDky jejich \u010Dast\u00FDm deregulac\u00EDm pat\u0159\u00ED mezi c\u00EDle modern\u00ED chemoterapie. \u00DA\u010Dinnost imatinobu p\u0159i l\u00E9\u010Db\u011B chronick\u00E9 myeloidn\u00ED leukemie poskytla jednozna\u010Dn\u00FD d\u016Fkaz o pou\u017Eitelnosti inhibitor\u016F proteinkinas jako l\u00E9\u010Div. Specifick\u00E1 rezistence n\u011Bkter\u00FDch pacient\u016F k imatinibu podn\u00EDtila v\u00FDvoj dal\u0161\u00EDch generac\u00ED l\u00E9\u010Div, kter\u00E9 tuto rezistenci obch\u00E1zej\u00ED. Tento \u010Dl\u00E1nek referuje o onkogenn\u00ED kinase Bcr-Abl jako p\u0159\u00EDkladu racion\u00E1ln\u00EDho c\u00EDle modern\u00ED chemoterapie a o pou\u017E\u00EDvan\u00FDch inhibitorech Bcr-Abl."@cs . . . "RIV/61989592:15310/08:00005482" . . . . . "The advances in understanding of neoplastic transformation considerably help to design molecularly targeted therapies. Protein kinases are critical components of cellular signaling pathways and due to their frequent deregulations in cancer cells they have become one of the most important targets for drug development. The efficiency of imatinib in treatment of chronic myeloid leukemia has provided a proof that kinase inhibitors can be effective drugs, although some patients develop resistance to them. However, structure-based design allows synthesizing of second-generation drugs that are able to overcome the resistance. The review focuses on oncogenic Bcr-Abl as an example of a rational target for kinase inhibitors, their development and biochemical properties."@en . "Onkogenn\u00ED kinasa Bcr-Abl a jej\u00ED rezistence k pou\u017E\u00EDvan\u00FDm inhibitor\u016Fm" . . . "Kry\u0161tof, Vladim\u00EDr" . "102" . "9" . . "0009-2770" . "CZ - \u010Cesk\u00E1 republika" . "imatinib; inhibitor; chronic myeloid leukaemia; kinase; cancer"@en . "Kinase Bcr-Abl and Its Resistance to Pharmacological Inhibitors"@en . "Onkogenn\u00ED kinasa Bcr-Abl a jej\u00ED rezistence k pou\u017E\u00EDvan\u00FDm inhibitor\u016Fm" . "1"^^ . "S, Z(MSM6198959216)" . . . "6"^^ . "RIV/61989592:15310/08:00005482!RIV09-MSM-15310___" . . "1"^^ . "Onkogenn\u00ED kinasa Bcr-Abl a jej\u00ED rezistence k pou\u017E\u00EDvan\u00FDm inhibitor\u016Fm"@cs . "15310" . "Onkogenn\u00ED kinasa Bcr-Abl a jej\u00ED rezistence k pou\u017E\u00EDvan\u00FDm inhibitor\u016Fm"@cs . "[2E4A75409EAE]" . "Kinase Bcr-Abl and Its Resistance to Pharmacological Inhibitors"@en . "384850" . "Pokroky ve studiu n\u00E1dorov\u00E9 transformace v\u00FDrazn\u011B usnad\u0148uj\u00ED n\u00E1vrhy modern\u00EDch a specifick\u00FDch terapeutick\u00FDch metod. Proteinkinasy pat\u0159\u00ED ke kli\u010Dov\u00FDm slo\u017Ek\u00E1m bun\u011B\u010Dn\u00FDch sign\u00E1ln\u00EDch soustav a d\u00EDky jejich \u010Dast\u00FDm deregulac\u00EDm pat\u0159\u00ED mezi c\u00EDle modern\u00ED chemoterapie. \u00DA\u010Dinnost imatinobu p\u0159i l\u00E9\u010Db\u011B chronick\u00E9 myeloidn\u00ED leukemie poskytla jednozna\u010Dn\u00FD d\u016Fkaz o pou\u017Eitelnosti inhibitor\u016F proteinkinas jako l\u00E9\u010Div. Specifick\u00E1 rezistence n\u011Bkter\u00FDch pacient\u016F k imatinibu podn\u00EDtila v\u00FDvoj dal\u0161\u00EDch generac\u00ED l\u00E9\u010Div, kter\u00E9 tuto rezistenci obch\u00E1zej\u00ED. Tento \u010Dl\u00E1nek referuje o onkogenn\u00ED kinase Bcr-Abl jako p\u0159\u00EDkladu racion\u00E1ln\u00EDho c\u00EDle modern\u00ED chemoterapie a o pou\u017E\u00EDvan\u00FDch inhibitorech Bcr-Abl." . . . . . "Chemick\u00E9 listy" . .